This is a working overview of preclinical research, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-19. Anything still debated is marked as such rather than presented as settled.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | LC-MS and HPLC | Used for identity and purity assessment. |
| Purity specification | ≥95% or ≥98% in research grades | Actual purity depends on supplier and batch. |
| Stability in solution | Limited; prepare fresh | Aqueous and organic stocks may degrade over time. |
| Recommended storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles. |
| Regulatory status | Not approved for human use | Sold as a research chemical in some regions. |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
== Signs and symptoms == In women, high blood levels of prolactin are typically associated with hypoestrogenism, anovulatory infertility, and changes in menstruation. Menstruation disturbances commonly manifests as amenorrhea or oligomenorrhea. While mild hyperprolactinemia may not always result in menstrual disorders, it is uncommon for women to have normal menstrual cycles if their serum prolactin levels exceed 180 ng/ml (3,600 mU/L). In such cases, irregular menstrual flow may result in abnormally heavy and prolonged bleeding (menorrhagia). Women who are not pregnant or nursing may also unexpectedly begin producing breast milk (galactorrhea), a condition that is not always associated with high prolactin levels. For instance, many pre-menopausal women experiencing hyperprolactinemia do not experience galactorrhea and only some women who experience galactorrhea will be diagnosed with hyperprolactinemia. Thus, galactorrhea may be observed in individuals with normal prolactin levels and does not necessarily indicate hyperprolactinemia. This phenomenon is likely due to galactorrhea requiring adequate levels of progesterone or estrogen to prepare the breast tissue. Additionally, some women may also experience loss of libido and breast pain, particularly when prolactin levels rise initially, as the hormone promotes tissue changes in the breast. In men, the most common symptoms of hyperprolactinemia are decreased libido, sexual dysfunction, erectile dysfunction/impotence, infertility, and gynecomastia.
Watanabe et al. (2026) report evidence from the study of genomes of the Jōmon people indicative of their descent from Upper Paleolithic continental East Asian populations that settled the Japanese archipelago between 27,000 and 19,000 years ago, and evidence of cold adaptation in the Jōmon lineage. Evidence from the study of stone tool assemblages from the Buhais Rockshelter (United Arab Emirates) indicative of repeated occupation of the studied area between 210,000 and 16,000 years ago (including in the time of overall increased aridity of the Arabian Peninsula between 60,000 and 16,000 years ago) is presented by Bretzke et al. (2026). Evidence from the study of Natufian artefacts and rock art from the Sahout site and the neighbouring sites of Jebel Arnaan and Jebel Misma (Saudi Arabia), indicative of occupation of the studied area by communities interacting with people from the Fertile Crescent during the terminal Pleistocene and early Holocene, is presented by Shipton et al. (2026). Davin et al. (2026) report the discovery of clay ornaments from Natufian (late Epipalaeolithic) sites in Israel, interpreted as produced both by adults and by children, and representing the earliest known clay ornamental tradition outside of Europe. Evidence of importance of consumption of lizards and snakes in subsistence strategies of Natufian foragers from the El Wad site (Israel) is presented by Lev, Weinstein-Evron & Yeshurun (2026).
Introduced in 1980, Jollibee is a large anthropomorphic bee mascot dressed in a red blazer, shirt, and chef's hat. Jollibee's design is based on Mickey Mouse. The mascot was designed to epitomize Filipino optimism. Tony Tan, Jollibee's founder, has compared the mascot's character to the Filipino working class, stating that the bee "hops around and produces sweet things for life, and is happy even though it is busy". The Jollibee mascot is an IPOPHL-registered well-known mark since 2025. Jollibee developed additional mascots, some of which were featured in Jollitown, a children's show aired in the Philippines.
Sources: en.wikipedia.org
== History == Because of its central geographic position within the Yugoslav federation, post-war Bosnia was strategically selected as a base for the development of the military defense industry. This contributed to a large concentration of arms and military personnel in Bosnia; a significant factor in the war that followed the break-up of Yugoslavia in the 1990s. However, Bosnia's existence within Yugoslavia, for the large part, was peaceful and prosperous. Being one of the poorer republics in the early 1950s it quickly recovered economically, taking advantage of its extensive natural resources to stimulate industrial development. The Yugoslavian communist doctrine of "brotherhood and unity" particularly suited Bosnia's diverse and multi-ethnic society that, because of such an imposed system of tolerance, thrived culturally and socially. The improvements to cultural tolerance throughout Bosnia and Herzegovina culminated with the selection of Sarajevo to host the 1984 Winter Olympics.
=== Safety of radiolabeled somatostatin receptor antagonists === In general, somatostatin receptor antagonists were noted to be well tolerated. However, due to its mechanism of action, it may decrease the effectiveness of SSA therapy (Somatostatin Analogue Therapy), but other studies indicate SSA may not need to be stopped if somatostatin antagonists are used to for tumor labelling instead of agonists. As somatostatin can cause inhibition of hormone production that uses it as a mediating hormone, it has an antiproliferative effect on cell tumors, especially in neuroendocrine tumors. Somatostatin analogue therapy uses longer-acting agonists than the endogenous somatostatin to extend the antiproliferative effects. Somatostatin receptor antagonists can bind to the receptors without activating them, antagonizing the therapeutic inhibitory effects of SSA therapy. Slow intravenous injection might be used until further safety data become available.
In this way, Project Gemini built up spaceflight experience for the pool of astronauts for the Apollo lunar missions. With the completion of Gemini, the US had demonstrated many of the key technologies necessary to make Kennedy's goal of landing a man on the Moon, namely crewed spacecraft docking, with the exception of developing a large enough launch vehicle.
Sources: en.wikipedia.org
== Relevance to immunology == Because fMet is present in proteins made by bacteria but not in those made by eukaryotes (other than in bacterially derived organelles), the immune system might use it to help distinguish self from non-self. Polymorphonuclear cells can bind proteins starting with fMet, and use them to initiate the attraction of circulating blood leukocytes and then stimulate microbicidal activities such as phagocytosis. Since fMet is present in proteins made by mitochondria and chloroplasts, more recent theories do not see it as a molecule that the immune system can use to distinguish self from non-self. Instead, fMet-containing oligopeptides and proteins appear to be released by the mitochondria of damaged tissues as well as by damaged bacteria, and can thus qualify as an "alarm" signal, as discussed in the Danger model of immunity. The prototypical fMet-containing oligopeptide is N-formylmethionine-leucyl-phenylalanine (FMLP) which activates leukocytes and other cell types by binding with these cells' formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2) G protein coupled receptors (see also formyl peptide receptor 3). Acting through these receptors, the fMet-containing oligopeptides and proteins are part of the innate immune system; they function to initiate acute inflammation responses but under other conditions function to inhibit and resolve these responses. fMet-containing oligopeptides and proteins also function in other physiological and pathological responses.
=== Legality === Levorphanol is listed under the Single Convention On Narcotic Drugs 1961 and is regulated like morphine in most countries. In the U.S., it is a Schedule II Narcotic controlled substance with a DEA ACSCN of 9220 and 2013 annual aggregate manufacturing quota of 4.5 kilograms. The salts in use are the tartrate (free base conversion ratio 0.58) and hydrobromide (0.76).
A recent systematic review and meta-analysis compared the results of published animal studies and identified that improved outcomes are reported with the use of hybrid (mixed) scaffolds and cell seeding; however, the meta-analysis of these results were not in agreement with the evaluation of descriptive results from the review. Therefore, further studies involving larger animals and novel scaffolds, and more transparent reproduction of previous studies are advisable.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.
Dihexa is often described as an HGF mimetic that activates c-Met signaling. Some research also links it to angiotensin IV pathways. The precise targets and human relevance remain uncertain.
The powder is typically stored at -20 °C, desiccated and protected from light. Avoid repeated freeze-thaw cycles. Follow supplier instructions and institutional guidelines.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.